A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV (Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC).

Trial Profile

A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV (Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2011

At a glance

  • Drugs Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 28 Oct 2011 Status changed from completed to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 28 Oct 2011 New source identified and integrated (M.D. Anderson Cancer Center).
    • 05 Jan 2011 Actual end date changed from Apr 2010 to Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top